ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluating the Influence of Ready-to-use (RTU) Parenteral Nutrition in the Clinical Outcome of Patients Study (EPICOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00798681
Recruitment Status : Completed
First Posted : November 26, 2008
Last Update Posted : August 10, 2010
Sponsor:
Collaborators:
Hospital Bandeirantes
Hospital Santa Luzia
Hospital Samaritano
Hospital da Polícia Militar
Sanatório Los Arcos
Sanatório Trinidad Palermo
Hospital Roosevelt
Information provided by:
Fernandes Tavora Hospital

November 25, 2008
November 26, 2008
August 10, 2010
July 2008
July 2010   (Final data collection date for primary outcome measure)
Incidence of bloodstreams and catheter infection, as well as incidence of sepsis, severe sepsis and septic shock. Sepsis diagnostic criteria will be re-evaluated on a daily basis. [ Time Frame: 28-day follow up ]
Same as current
Complete list of historical versions of study NCT00798681 on ClinicalTrials.gov Archive Site
  • 28-days all cause mortality [ Time Frame: 28-days follow-up period ]
  • Time to start parenteral nutrition, defined as the time from prescription to the effective start of infusion [ Time Frame: Time from prescription to the effective start of TPN ]
  • Incidence of hyperglycemic events, defined as the number of times patients developed blood glucose levels over 110 mg/dL and over 150 mg/dL [ Time Frame: For the duration of TPN ]
  • Incidence of hypoglycemic events: defined as the number of times patients developed blood glucose levels bellow 60 mg/dL [ Time Frame: For the duration of TPN ]
  • Mean dose of insulin used (patients will receive insulin in order to maintain blood glucose levels <150 mg/dL (or 8.3 mmol/L) in accordance with the Surviving Sepsis Campaign Guidelines) [ Time Frame: For the duration of TPN ]
  • Use of hospital/ICU resources such as vasopressors, mechanical ventilation, need of hemodialysis, need of inotropic agents, antibiotics and sedatives [ Time Frame: 28-days follow-up period ]
  • ICU-free days, defined as the number of days from study entry (baseline) to the actual day that a patient remained on the ICU during the 28-days follow up period [ Time Frame: 28-days follow-up period ]
  • Number of new organ failures [ Time Frame: 28-days follow-up period ]
  • 28-days all cause mortality [ Time Frame: 28-days follow-up period ]
  • Time to start parenteral nutrition, defined as the time from prescription to the effective start of infusion [ Time Frame: Time from prescription to the effective start of TPN ]
  • Incidence of hyperglycemic events, defined as the number of times patients developed blood glucose levels over 110 mg/dL and over 150 mg/dL [ Time Frame: For the duration of TPN ]
  • Incidence of hypoglycemic events: defined as the number of times patients developed blood glucose levels bellow 40 mg/dL [ Time Frame: For the duration of TPN ]
  • Mean dose of insulin used (patients will receive insulin in order to maintain blood glucose levels <150 mg/dL (or 8.3 mmol/L) in accordance with the Surviving Sepsis Campaign Guidelines) [ Time Frame: For the duration of TPN ]
  • Use of hospital/ICU resources such as vasopressors, mechanical ventilation, need of hemodyalisis, need of inotropic agents, antibiotics and sedatives [ Time Frame: 28-days follow-up period ]
  • ICU-free days, defined as the number of days from study entry (baseline) to the actual day that a patient remained on the ICU during the 28-days follow up period [ Time Frame: 28-days follow-up period ]
  • Number of new organ failures [ Time Frame: 28-days follow-up period ]
  • Evolution of the SOFA score [ Time Frame: 28-days follow-up period ]
Not Provided
Not Provided
 
Evaluating the Influence of Ready-to-use (RTU) Parenteral Nutrition in the Clinical Outcome of Patients Study
EPICOS- Evaluating the Influence of RTU Parenteral Nutrition in the Clinical Outcome Patients Study
This is an international prospective randomized multicenter open-label controlled study. The primary center will be Fernandes Távora Hospital (Fortaleza, Ceará). The aim of this study is to investigate the effects of closed parenteral nutrition systems when compared to open parenteral nutrition systems in terms of several clinical outcomes.

In most Latin-American countries individually customized nutrition formulations (CNF) remains the gold-standard for parenteral nutrition in opposition to industrialized ready-to-use parenteral nutrition (RTU). Although CNF is possibly associated with elevated infection rates, delay in the start of enteral nutrition and worse clinical outcomes there is no strong scientific evidence in the literature to support that the use of RTU is indeed associated with better clinical outcomes.

The use of closed ready-to-use parenteral nutrition systems is probably associated with less infection rates and better clinical outcomes including less time at the hospital and at the intensive care unit, less consumption of hospital resources and most likely lower mortality rates as well as early initiation of parenteral nutrition support. The aim of this study is to evaluate all the above mentioned parameters in contrast with those observed when using CNF parenteral nutrition.

Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Parenteral Nutrition
  • Dietary Supplement: RTU TPN with olive oil as the primary lipid source
    RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.
    Other Name: OliClinomel, Baxter Healthcare
  • Other: CNF Parenteral nutrition
    CNF parenteral nutrition made with olive oil as the primary source of lipids
    Other Name: ClinOleic, Baxter Healthcare
  • Other: CNF parenteral nutrition
    3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
    Other Name: LCT/MCT providers may vary
  • Experimental: 1
    Patients will receive RTU TPN with olive-oil as the primary source of lipids
    Intervention: Dietary Supplement: RTU TPN with olive oil as the primary lipid source
  • Active Comparator: 2
    CNF parenteral nutrition made with olive oil as the primary source of lipids
    Intervention: Other: CNF Parenteral nutrition
  • Active Comparator: 3
    CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
    Intervention: Other: CNF parenteral nutrition
Pontes-Arruda A, Dos Santos MC, Martins LF, González ER, Kliger RG, Maia M, Magnan GB; EPICOS Study Group. Influence of parenteral nutrition delivery system on the development of bloodstream infections in critically ill patients: an international, multicenter, prospective, open-label, controlled study--EPICOS study. JPEN J Parenter Enteral Nutr. 2012 Sep;36(5):574-86. Epub 2012 Jan 23.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
406
400
July 2010
July 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients over 18 years of age with recommendation to use total parenteral nutrition.
  • Caloric goals will be calculated using BEE adjusted by the pathology of the patient. In addition, patients MUST achieve at least once 75% of BEE (calculated using the Harris-Benedict equation) to be considered evaluable. Caloric intake will be accessed in a daily basis.
  • This study will be performed in accordance with all ethics statements of the Helsinki's Declaration (52nd General Assembly of the World Medical Association, Edinburgh, Scotland, October, 2000), and of the Nuremberg Code.
  • In addition, this study must be approved by the Institutional Review Board before patient enrollment and by the Federal Council of Research and Ethics of the Ministry of Health.
  • All participating institutions will also be requested to observe Good Clinical Practice Guidelines and all federal laws and regulations.
  • An informed consent will be obtained from all patients or their legal representatives before any study related procedure.

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Patients under 18 years of age
  • Significant limitation of survival prognosis (patients expecting a life survival under 28 days due to a chronic and/or incurable disease such as uncontrolled cancer or other terminal disease)
  • Pre-existing chronic renal insufficiency and need of hemodialysis or peritoneal dialysis, participation in other clinical trial less than 3 months before inclusion in this trial
  • Head trauma with a Glasgow Come Score (GCS) less or equal to 5
  • Severe immunologic suppression (defined as a leukocyte count bellow 5.000 cells/mm3)
  • Infection by the human immunodeficiency virus
  • Patients with no indication for parenteral feeding or in the imminence of receiving enteral nutrition
  • Patients receiving partial parenteral nutrition in order to achieve caloric goal, or patient's, patient's legal representative or physicians decision to exclude patients from this protocol.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Brazil,   Guatemala
 
 
NCT00798681
HFT-001/2008-BR
Yes
Not Provided
Not Provided
Alessandro Pontes-Arruda, MD MSc PhD FCCM, Fernandes Tavora Hospital
Fernandes Tavora Hospital
  • Hospital Bandeirantes
  • Hospital Santa Luzia
  • Hospital Samaritano
  • Hospital da Polícia Militar
  • Sanatório Los Arcos
  • Sanatório Trinidad Palermo
  • Hospital Roosevelt
Principal Investigator: Alessandro Pontes-Arruda, MD, MSc, PhD, FCCM Fernandes Tavora Hospital
Fernandes Tavora Hospital
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP